CoChat

Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

Open access
Raccah, Denis, Miossec, Patrick, Esposito, Virginie, Niemoeller, Elisabeth, Cho, Meehyung, Gerich, John · 2015 · Diabetes/Metabolism Research and Reviews
Cited by 50

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background: The objective of this article is to evaluate the pharmacokinetics, efficacy and safety of lixisenatide (subcutaneous injection) in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes mellitus. Methods: We conducted a phase I, single‐centre, open‐label study to evaluate the safety and pharmacokinetics of a single lixisenatide 20 µg dose and a pooled analysis of six randomized, placebo‐controlled, phase III studies (12‐month or 24‐month duration) that evaluated glycaemic parameters and safety in patients receiving lixisenatide 20 µg once daily or placebo. Results: The pharmacokinetics study included 36 healthy subjects, including 18 elderly healthy subjects (≥65 years old) and 18 matched young healthy subjects (18–45 years old). The pooled analysis included 3188 patients, including 2565 patients <65 years old and 623 patients ≥65 years old (including 79 patients ≥75 years old). Mean exposure with lixisenatide 20 µg was ~30% higher in elderly than in young subjects, and the terminal half‐life was prolonged by ~1.6 times. Maximum concentration (C max) and time to C max (t max) were comparable in both groups. Equal numbers of elderly and young subjects reported treatment‐emergent adverse events, the majority of which were gastrointestinal disorders. In the pooled analysis, lixisenatide 20 µg once daily provided significant reductions in HbA 1c versus placebo for all age groups. There was a similar incidence of treatment‐emergent adverse events across all age groups (range: 69–73%). The incidence of symptomatic hypoglycaemia was generally comparable between lixisenatide‐treated and placebo‐treated patients. Conclusion: These data suggest that lixisenatide is effective and well tolerated in elderly and very elderly patients with type 2 diabetes mellitus. © 2014 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.2588

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 50

Metadata

Authors
Raccah, D., Miossec, P., Esposito, V., Niemoeller, E., Cho, M., & Gerich, J.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2014-09-16
Volume
31
Issue
2
Pages
204-211
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W1568556160
Cited by
50
References
16
FWCI
4.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. https://app.cochat.ai/papers/10.1002/dmrr.2588
The paper
Raccah, D., Miossec, P., Esposito, V., Niemoeller, E., Cho, M., & Gerich, J. (2015). Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.2588

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.